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Abstract
Background: Cerebral microhemorrhages (CMH) are tiny deposits of blood degradation products in the brain and
are pathological substrates of cerebral microbleeds. The existing CMH animal models are β-amyloid-, hypoxic brain
injury-, or hypertension-induced. Recent evidence shows that CMH develop independently of hypoxic brain injury,
hypertension, or amyloid deposition and CMH are associated with normal aging, sepsis, and neurodegenerative
conditions. One common factor among the above pathologies is inflammation, and recent clinical studies show a
link between systemic inflammation and CMH. Hence, we hypothesize that inflammation induces CMH development
and thus, lipopolysaccharide (LPS)-induced CMH may be an appropriate model to study cerebral microbleeds.
Methods: Adult C57BL/6 mice were injected with LPS (3 or 1 mg/kg, i.p.) or saline at 0, 6, and 24 h. At 2 or
7 days after the first injection, brains were harvested. Hematoxylin and eosin (H&E) and Prussian blue (PB)
were used to stain fresh (acute) hemorrhages and hemosiderin (sub-acute) hemorrhages, respectively. Brain
tissue ICAM-1, IgG, Iba1, and GFAP immunohistochemistry were used to examine endothelium activation,
blood-brain barrier (BBB) disruption, and neuroinflammation. MRI and fluorescence microscopy were used to
further confirm CMH development in this model.
Results: LPS-treated mice developed H&E-positive (at 2 days) and PB-positive (at 7 days) CMH. No surface and
negligible H&E-positive CMH were observed in saline-treated mice (n = 12). LPS (3 mg/kg; n = 10) produced
significantly higher number, size, and area of H&E-positive CMH at 2 days. LPS (1 mg/kg; n = 9) produced
robust development of PB-positive CMH at 7 days, with significantly higher number and area compared
with saline (n = 9)-treated mice. CMH showed the highest distribution in the cerebellum followed by the
sub-cortex and cortex. LPS-induced CMH were predominantly adjacent to cerebral capillaries, and CMH load was
associated with indices of brain endothelium activation, BBB disruption, and neuroinflammation. Fluorescence
microscopy confirmed the extravasation of red blood cells into the brain parenchyma, and MRI demonstrated the
presence of cerebral microbleeds.
Conclusions: LPS produced rapid and robust development of H&E-positive (at 2 days) and PB-positive (at 7 days) CMH.
The ease of development of both H&E- and PB-positive CMH makes the LPS-induced mouse model suitable to study
inflammation-induced CMH.
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Background
Cerebral microhemorrhages (CMH) are tiny perivascular
deposits of blood degradation products in the brain and
are the pathological substrate of cerebral microbleeds
[1]. In spite of the significant clinical and scientific inter-
est in this field, lack of appropriate animal models has
hindered progress in delineating the exact mechanisms
involved in CMH development and in the development
of treatments to address CMH. The currently used
animal models of CMH are amyloid beta (Aβ)- [2–4],
hypoxia-reoxygenation-, or hypertension-induced [5].
These existing animal models have several disadvan-
tages: (1) CMH development in these models can take
up to 15–24 months, (2) invasive surgical procedures
are required to exacerbate CMH development, and
most importantly, (3) clinically, CMH may develop
independent of amyloid deposition, hypoxic brain
injury, or hypertension [6].
It is now well recognized that CMH are not only asso-
ciated with cerebrovascular diseases including stroke,
cerebral amyloid angiopathy (CAA), and cerebral hyper-
tensive vasculopathy [1] but are also found in patients
with sepsis [7], Parkinson’s disease [8], chronic obstruct-
ive pulmonary disease (COPD) [9], and traumatic brain
injury (TBI) [10] and in normal aging adults [1]. One
common feature of these entities is systemic inflamma-
tion [11], and recent human studies show a link between
systemic inflammation and CMH pathogenesis. Higher
levels of peripheral inflammatory markers are associated
with cerebral microbleeds in aging patients [12], high
levels of circulating tumor necrosis factor receptor 2
are observed in subjects with cerebral microbleeds
[13], and higher activity of lipoprotein phospholipase-
A2 (a marker of vascular inflammation) is related to
the presence of deep cerebral microbleeds in subjects
who were carriers of at least one APOE ε2 or ε4
allele [14]. While inflammation may be central to the
development of CMH, a direct causal link between in-
flammation and CMH development has been lacking.
Hence, we hypothesized that systemic inflammation will
induce CMH development and that an inflammation-
induced animal model will be appropriate to study CMH
development and treatment.
To test this hypothesis, we used lipopolysaccharide
(LPS), a well-characterized standardized inflammatory
stimulus, to study CMH development. Previous studies
from our lab showed that mice treated with a 5 mg/kg
dose of LPS at 0 and 24 h had a significantly higher
number of CMH at 2 days as evident by hematoxylin
and eosin (H&E)-positive staining in brain tissue com-
pared with controls. We now report a well-characterized
inflammation-induced mouse model of CMH with low
mortality, using different dosing regimens (1 or 3 mg/kg,
i.p., at 0, 6, and 24 h, and sacrifice at 2 or 7 days) of LPS.
In the current study, we examined both acute CMH
(H&E-positive) at 2 days and sub-acute CMH (Prussian
blue/hemosiderin-positive) at 7 days. The number, size,
total area, and neuroanatomical distribution of CMH
were examined in the LPS- and saline-treated mice. To
elucidate mechanisms involved in LPS-induced CMH,
we analyzed markers of brain endothelial damage
(ICAM-1 and parenchymal IgG) and neuroinflammation
(astrocyte and microglia/macrophages). The vascular
source of LPS-induced CMH was examined, and we also
used fluorescence microscopy to confirm acute CMH
development and magnetic resonance imaging (MRI) to




All animal procedures were approved by the UCI
Institutional Animal Care and Use Committee and were
carried out in compliance with the University Laboratory
Animal Resources regulations. Adult (male and female
10–12 weeks old) C57BL/6 mice (Taconic, Hudson, NY)
were used for all the experiments. In the first set of ex-
periments, the mice were treated with either a 3 mg/kg
dose of LPS derived from Salmonella typhimurium
(Sigma, St. Louis, MO) or saline i.p. at 0, 6, and 24 h
and sacrificed 2 days after the first injection to examine
acute CMH development. In a separate series of experi-
ments, the mice were treated with a 1 mg/kg dose of
LPS or saline at 0, 6, and 24 h and sacrificed 7 days after
the first injection to examine sub-acute CMH develop-
ment. The mice fed and drank ad lib and received up to
three times daily doses of 1 cm3 saline subcutaneously.
Two or 7 days after the first injection, mice were anes-
thetized with a lethal dose of Nembutal (150 mg/kg,
i.p.), cardiac perfusions were performed using ice-cold
PBS for 5 min to clear the cerebral vasculature, and
brains were processed for CMH detection.
Microhemorrhage detection
Brains were fixed in 4 % paraformaldehyde at 4 °C for
72 h, examined for surface microhemorrhages, and sec-
tioned into 40-μm coronal sections using a vibratome
(Technical Products International, Inc., St. Louis, MO).
Every sixth section was collected and stained with either
H&E to detect fresh (acute) microhemorrhages in the 2-
day study or Prussian blue (PB) to detect hemosiderin (a
marker of sub-acute microhemorrhage) in the 7-day
study. PB was not used for the 2-day study, based on
findings of our earlier work [15]. A total of approxi-
mately 30 brain sections were analyzed per mouse. For
PB staining, sections were stained using freshly made
5 % potassium hexacyanoferrate trihydrate (Sigma, St.
Louis, MO) and 5 % hydrochloric acid (Sigma, St. Louis,
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MO) for 30 min, rinsed in water and counterstained
with Nuclear Fast Red (Sigma, St. Louis, MO), dehy-
drated, and cover-slipped. H&E staining was performed
by Research Services Core offered by the Department of
Pathology and Laboratory Medicine at the UCI Medical
Center. CMH were counted at a ×20 magnification by a
blinded observer as a collection of red blood cells (RBC)
that appear red-orange using H&E stain and as clear
purple-blue deposits using PB. Digitized images were
obtained using an Olympus BX40 microscope and CC-
12 Soft-Imaging System with Olympus MicroSuite
(TM)-B3SV software. CMH size (μm2) and positive area
(expressed as a percent of total area analyzed) were de-
termined by an observer blinded to the experiment using
the NIH ImageJ software 1.62. When the vessel associ-
ated with the CMH was visible, internal diameter of the
blood vessel was determined using the NIH ImageJ soft-
ware 1.62.
ICAM-1, IgG, Iba1, and GFAP immunohistochemistry
To determine the role of endothelial damage and
neuroinflammation in LPS-induced CMH develop-
ment, ICAM-1 (marker of endothelial cell activation),
parenchymal IgG (blood-brain barrier (BBB) damage
marker), Iba1 (microglia/macrophage marker), and
GFAP (astrocyte marker) immunohistochemistry were
performed. Briefly, 40-μm sections from mice treated
with LPS and saline from the 2-day study were incu-
bated in 0.5 % hydrogen peroxide in 0.1 M PBS (pH
7.4) containing 0.3 % Triton-X100 (PBST) for 30 min
at room temperature to block endogenous peroxidase
activity. After washing with PBST, sections were incu-
bated for 30 min with PBST containing 2 % bovine
serum albumin to block non-specific protein binding.
Sections were then incubated overnight at 4 °C with a
rabbit anti-mouse IgG antibody (1:200 dilution; Jack-
son ImmunoResearch, West Grove, PA), rabbit mono-
clonal antibody against ICAM-1 (1:500 dilution;
Abcam, Cambridge, MA), rabbit antibody against Iba1
(1:200 dilution, Wako Chemicals USA, Richmond,
VA), or rabbit antibody against GFAP (1:2000 dilu-
tion, Abcam, Cambridge, MA). After washing with
PBST, sections were incubated at room temperature
for 1 h with biotinylated anti-rabbit IgG (1:500 dilu-
tion; Jackson ImmunoResearch, West Grove, PA),
followed by 1-h incubation at room temperature with
ABC complex according to the manufacturer instruc-
tions (Vector Laboratories, Burlingame, CA). Sections
were developed with 3,3′-diaminobenzidine (DAB)
(Vector Laboratories, Burlingame, CA). Sixteen im-
ages per brain section were acquired at ×20 magnifi-
cation, and the total positive immunoreactive area
was quantified using the NIH ImageJ software by an
observer blinded to the experimental groups.
Immunopositive area was expressed as percent of
total area analyzed.
Magnetic resonance imaging
MRI was performed to confirm the radiographic presence
of cerebral microbleeds in this model using a randomly
selected subset of mouse brains after completion of
the 7-day experiment. Mouse brains were collected
post mortem after cardiac perfusion with PBS to clear
vasculature of blood, followed by fixation in 4 %
paraformaldehyde; imaging was performed prior to
sectioning. Data were acquired using a Bruker 7T
small-animal MRI machine with a 12-cm gradient, a
660 m/T/m strength and 4570 slew rate, and a 1-cm
receive-only surface coil. The pulse sequence used
was a 3D FLASH (fast low-angle shot) gradient echo
sequence. TE was 12 ms, TR was 30.2 ms, and FA
was 11°. Voxel size was 100 × 100 × 156 μm. The MRI
data was manually processed and surface-rendered
using Amira software (FEI, Hillsboro, OR).
Ex vivo optical microscopy imaging
In a separate series of experiments, the transit of RBC
across the cerebral vasculature into the brain paren-
chyma was visualized using ex vivo confocal and two-
photon-excited fluorescence (TPEF) microscopy. Briefly,
autologous blood was collected from inbred Tie2-GFP
mice (Jackson Laboratory, Bar Harbor, ME) in which
endothelial cells are labeled with green fluorescent pro-
tein (GFP), and RBC were purified using Ficoll-Paque
(GE Healthcare, Uppsala, Sweden) gradient. After several
washes in PBS, RBC were stained with PKH26 Red
Fluorescent Cell Linker Kit (Sigma, St. Louis, MO)
according to the manufacturer’s instructions and re-
injected into the mice. Immediately after RBC injection,
the mice were subjected to either saline or LPS triple-
dosing regimen (3 mg/kg, i.p., 0, 6, and 24 h) as per the
2-day experiment described earlier. The mice were sacri-
ficed 48 h after the first saline or LPS injection, and
whole brains were collected and fixed in 4 % paraformal-
dehyde for imaging. Fluorescence and second-harmonic
generation (SHG) images of whole brains fixed in 4 %
paraformaldehyde were obtained using Zeiss LSM 510
Meta NLO microscopy system equipped with a long
working distance Zeiss 40 × 0.8 water immersion object-
ive. GFP fluorescence was excited by 488-nm line of the
Argon laser; PKH26 excitation was provided by He-Ne
543-nm laser, and SHG signal from collagen was gener-
ated using a Chameleon Ultra femtosecond pulsed tun-
able laser (Coherent Inc., Los Angeles, CA) at 800 nm.
Two confocal fluorescence channels (green emission at
500–530 nm and red emission at 565–615 nm) were ac-
quired simultaneously, and SHG image (blue emission
filter 390–465 nm) was acquired consequently. Laser
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scanning did not induce any visible damage to the cells
or noticeable bleaching of the sample. Stacks of images
were acquired with the z-step (distance between con-
secutive imaging planes) of 2.5 μm. The maximum depth
for imaging was up to 80 μm from the brain surface.
The probed 3D volume was reconstructed by Zeiss LSM
original software.
Statistical analysis
Data were represented as mean ± SEM, and all statistical
analysis was performed using GraphPad Prism 5
(GraphPad Software Inc., La Jolla, CA). Student’s t test
(for normally distributed data) or Mann-Whitney U test
(for non-normal data) was used to compare two groups.
One- and two-way ANOVA (with and without repeated
measures) with Bonferroni’s post hoc test were used to
compare more than two groups. Spearman’s rho correl-
ation was used for correlation analysis. A p value of <0.05
was considered statistically significant.
Results
Survival
For the 2-day experiment, all 12 mice in the saline group
survived the duration of the study; however, one mouse
in the LPS group died before the end of the study, and
two were excluded due to incomplete perfusion, giving
us a total of ten mice in the LPS group. All mice (n = 9
per group) survived the 7-day experiment.
Surface cerebral microhemorrhages
In the 2-day experiment, a 3 mg/kg dose of LPS at 0, 6,
and 24 h induced the development of grossly visible sur-
face CMH (7.4 ± 2.2 per brain), compared with saline
controls that exhibited no surface CMH (p < 0.01)
(Fig. 1a–c). Regional differences were observed in the
location of these surface CMH. In the LPS-treated
group, the average number of surface CMH per brain
was significantly higher in the cerebellum/brain stem
(4.7 ± 1.6) compared with the olfactory bulb (1.8 ± 0.6, p
< 0.05) and the cerebral cortex (0.9 ± 0.3, p < 0.01)
(Fig. 1a). In mice treated with a 1 mg/kg dose of LPS at
0, 6, and 24 h and sacrificed 7 days after the first in-
jection, the average number of surface CMH (1.2 ± 0.4
per brain) was significantly higher compared with the
saline-treated mice, which again exhibited no surface
CMH (p < 0.05; Fig. 1d).
Acute parenchymal cerebral microhemorrhages
In the 2-day experiment, a 3 mg/kg dose of LPS at 0, 6,
and 24 h significantly induced (p < 0.0001 vs saline con-
trol) the formation of fresh H&E-positive parenchymal
CMH (1.3 ± 0.3 vs 0.03 ± 0.02 per brain section). H&E-
positive CMH were observed in all LPS-treated mice
(ranging from 0.4 to 2.9 per brain section). Regional
differences were observed in the distribution of H&E-
positive CMH in the LPS-treated mice (Fig. 2a, b). The
number of H&E-positive CMH was the highest in the
cerebellum/brain stem (1.6 ± 0.4 per brain section)
followed by the sub-cortical (0.8 ± 0.2 per brain section,
p < 0.0001 vs cerebellum and p < 0.05 vs cortex) and the
cortical (0.4 ± 0.09 per brain section, p < 0.0001 vs cere-
bellum) regions of the brains of LPS-treated mice. No
regional differences were observed in the distribution of
H&E-positive CMH in the saline-treated mice (cortex
0.01 ± 0.007, sub-cortex 0.01 ± 0.007, and cerebellum/
brain stem 0.05 ± 0.04 per brain section). H&E-positive
CMH were also examined in the 7-day study to see if acute
CMH continued to develop after LPS injections were
stopped at 2 days. No significant differences in the number
of H&E-positive CMH were found between the LPS- and
saline-treated mice in the 7-day study (data not shown).
A total of 68 blood vessels associated with H&E-
positive CMH were visible and studied in the current
study. Of these, 51 were <10 μm in diameter (mean
diameter 5.6 ± 0.04 μm) and 17 were between 10 and
30 μm in diameter (mean diameter 15.8 ± 1.7 μm). The
mean diameter of the vessels associated with the H&E-
positive CMH was 8.2 ± 0.09 μm (Fig. 2c), and the blood
vessels ranged from 1.5 to 30 μm in diameter.
Approximately 30 sections per mouse brain were
examined in the current study. To study the size dis-
tribution of the parenchymal CMH, all observed
CMH from all the mice in each group were studied.
A total of 616 (from n = 10) and 9 (from n = 12)
H&E-positive CMH were analyzed in the LPS- and
saline-treated groups, respectively. H&E-positive CMH
ranged from 136 to 1684 μm2 in the saline group and
from 63 to 3.9 × 106 μm2 in the LPS group (Fig. 3a). LPS
produced H&E-positive CMH that were significantly lar-
ger in size compared with saline controls (p < 0.0001). The
mean size of H&E-positive CMH was 2649 ± 306 and
246 ± 145 μm2 in the LPS- and saline-treated mice,
respectively (Fig. 3b). Total H&E-positive CMH area
(or total CMH load, is a function of both the number
and size of microhemorrhages) was significantly higher
(p < 0.0001) in the LPS- compared with the saline-
treated group (0.01± 0.004 % vs 4.8 x 10-5 ± 2.7 x
10-5 % of total brain section analyzed area) (Fig. 3c).
The weights of the mice at the beginning and end of
the 2-day study were 21.8 ± 0.9 and 21.3 ± 0.8 g in the
LPS group and 21.9 ± 0.7 and 22.6 ± 0.76 g in the sa-
line group, respectively.
Sub-acute parenchymal cerebral microhemorrhages
PB-positive stains were detected in both mice treated
with saline and 1 mg/kg dose of LPS at 0, 6, and 24 h
and sacrificed at 7 days. However, the mean number of
PB-positive stains was significantly higher (p < 0.0001) in
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the LPS-treated group (1.9 ± 0.2 per brain section) com-
pared with saline control (0.8 ± 0.1 per brain section)
(Fig. 4a). Similar to H&E-positive fresh CMH, PB-posi-
tive stains showed differences in regional distribution
among the LPS-treated mice (Fig. 4b, c). The number of
PB-positive stains was significantly higher in the cerebel-
lum/brain stem (1.9 ± 0.3 per brain section) compared
with the cortical (1.0 ± 0.1 per brain section, p <
0.0001) and the sub-cortical (0.9 ± 0.1 per brain sec-
tion, p < 0.0001) regions of the brains of LPS-treated
mice. No regional differences were observed in the
distribution of PB-positive stains in the saline-treated
mice (cortex 0.6 ± 0.09, sub-cortex 0.3 ± 0.08, and
cerebellum/brain stem 0.5 ± 0.1 per brain section). A
total of 466 (from n = 9) and 231 (from n = 9) PB-
positive stains were analyzed in the LPS- and saline-
treated groups, respectively. PB-positive stains ranged
from 9 to 29,377 μm2 among the LPS mice and from
14 to 4888 μm2 among the saline-treated mice. The
average PB-positive stain size was not significantly
different in the LPS- and saline-treated mice (data
not shown). The total PB-positive area was signifi-
cantly (p < 0.01) higher in the LPS-treated mice
(0.002 ± 0.0006 % of total brain section area analyzed)
compared with saline controls (0.0006 ± 0.0001 % of
total brain section area analyzed) (Fig. 4c). For the 7-
day study, the average weights of the mice at the be-
ginning and end of the study were 21.0 ± 0.6 and
22.1 ± 0.7 g among the saline mice and 20.7 ± 1 and
20.6 ± 0.7 g among the LPS mice.
Correlation between CMH development and brain
endothelial damage
Immunohistochemical analysis using sections (eight
mice from the LPS-treated group and four mice from
the saline-treated group) from the 2-day experiment
revealed that ICAM-1-positive area was significantly
associated with the number of CMH per brain section
(r = 0.86, p < 0.001) and total CMH-positive area (or
CMH load) expressed as % total area (r = 0.70, p < 0.01).
Fig. 1 Significant development of surface microhemorrhages in
mice treated with LPS (n = 10) (3 mg/kg at 0, 6, and 24 h) compared
with saline-treated mice (n = 12) and regional differences in the
distribution of surface microhemorrhages in LPS-treated mice (a) in
the 2-day experiment. Brain images showing absence of surface
microhemorrhages in saline-treated mice (b) and presence of surface
microhemorrhages in the olfactory bulb (left panel) and the cerebellum
(right panel) of LPS-treated mice (c). Significantly higher surface
microhemorrhages in mice treated with LPS (n = 9) (1 mg/kg at
0, 6, and 24 h) compared with the saline-treated mice (n = 9)
in the 7-day experiment (d). Data are presented as mean ± SEM.
Student’s t test for two groups and one-way ANOVA with Bonferroni’s
post-test for more than two groups; *p < 0.05, **p < 0.01
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IgG-positive area was significantly associated with CMH
size (r = 0.56, p < 0.05) and total CMH-positive area (or
CMH load) (r = 0.53, p < 0.05), as shown in Table 1.
Correlation between CMH development and
neuroinflammation
Immunohistochemical analysis using brain sections
(seven mice from the LPS-treated group and four mice
from the saline-treated group) from the 2-day experi-
ment showed that the total Iba1- and GFAP (markers of
neuroinflammation)-positive immunoreactive areas were
significantly higher in the LPS-treated mice compared
with the saline controls (Fig. 5a–c). Further, both Iba1-
and GFAP-positive immunoreactive areas were signifi-
cantly associated with the number (Iba1 r = 0.85, p <
0.01; GFAP r = 0.83, p < 0.01; Fig. 5d), size (Iba1 r = 0.72,
p < 0.01; GFAP r = 0.62, p < 0.05), and total CMH load
(Iba1 r = 0.88, p < 0.001; GFAP r = 0.85, p < 0.001), as shown
in Table 1.
Apart from histochemistry, in the current model, the de-
velopment of parenchymal CMH and cerebral microbleeds
was further confirmed by two separate methodologies. In
the 2-day experiment, ex vivo confocal fluorescence
microscopy showed the transit of fluorescently labeled
RBC (PKH26 labeled red RBC; Fig. 6a, b) across the
cerebral vascular endothelium (GFP labeled green
endothelium; Fig. 6a, b) into the brain parenchyma in
the LPS-treated mice (Fig. 6b) but not the saline-
treated mice (Fig. 6a). In the 7-day experiment, MRI
confirmed robust development of cerebral micro-
bleeds in the LPS-treated mice (Fig. 6c).
Discussion
In the current study, we have developed and character-
ized an LPS-induced inflammation mouse model of
CMH that shows rapid and robust development of
CMH. As early as 2 days following an intraperitoneal
LPS triple-dosing regimen (3 mg/kg at 0, 6, and 24 h),
H&E-positive (acute) CMH were observed in mice. PB-
positive CMH were observed in mice at 7 days following
Fig. 2 Acute H&E-positive cerebral microhemorrhages: Significant
development of acute (H&E-stained) parenchymal microhemorrhages
in mice treated with LPS (n = 10) (3 mg/kg, at 0, 6, and 24 h) compared
with saline-treated mice (n = 12) (comparisons shown in black)
(a). Significant difference in regional distribution of H&E-positive
parenchymal microhemorrhages in the LPS-treated group (comparisons
shown in blue) (a). Representative images showing H&E-positive cerebral
microhemorrhages in the cortex, sub-cortex, and cerebellum of LPS- and
saline-treated mice (b). Representative image showing a cerebral blood
vessel associated with an acute (H&E-positive) cerebral microhemorrhage
(c). Data are presented as mean ± SEM. Two-way repeated measure
ANOVA with Bonferroni’s post-test; *p< 0.05, **p<0.01, ****p< 0.0001.
Scale bar = 100 μm
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a modified intraperitoneal LPS triple-dosing regimen
(1 mg/kg at 0, 6, and 24 h). Both the H&E- and PB-
positive lesions showed similar neuroanatomical distri-
bution patterns, with the highest number of CMH
located in the cerebellum followed by the sub-cortex
and cortex. The total CMH load was significantly associ-
ated with markers of cellular activation (endothelium,
astrocyte, and microglia/macrophage) and BBB disrup-
tion. Finally, MRI confirmed the presence of cerebral
microbleeds in this LPS-induced inflammation mouse
model.
Systemic inflammation and an increase in inflamma-
tory markers have been associated with normal aging
[11], stroke [16–18], and peripheral conditions including
sepsis [19] and hypertension [20]. Active inflammation
can cause endothelial damage and BBB disruption [21],
and it is speculated that these events allow extravasation
of erythrocytes from the blood vessel lumen into the brain
parenchyma, resulting in CMH development [22]. In
fact, recent studies show an association between ac-
tive inflammation and CMH [12, 13]. Inflammation
may thus produce vascular dysfunction that triggers
or potentiates CMH development.
LPS is a well-studied inflammatory stimuli used in
rodent models of acute inflammation [23] that causes
BBB damage [24] and brain endothelial dysfunction
[25, 26]. These characteristics of LPS make it a well-
suited stimulus for the development of inflammation-
induced CMH. We have previously shown that two
intraperitoneal injections of LPS (5 mg/kg at 0 and
24 h) result in the development of H&E-positive
CMH in C57BL/6 mice, at 2 days after the first LPS
injection [15]. In the current study, we used a modi-
fied dosing regimen, adapted from a published study
[27] and found that triple intraperitoneal injections of
LPS (3 mg/kg at 0, 6, and 24 h) result in rapid (as
early as 2 days) development of H&E-positive CMH,
with negligible mortality.
Fig. 3 Size and area of acute H&E-positive CMH: Size distribution of all the H&E-positive CMH analyzed in the LPS (n = 10) (3 mg/kg, at 0, 6, and
24 h)- and saline (n = 12)-treated mice (a). The width of each bar is 1000 μm2, and the bin center for each bar is shown on the X-axis. H&E-
stained cerebral microhemorrhage average size (b) and positive area (c) are significantly higher in LPS-treated (3 mg/kg, at 0, 6, and 24 h) mice
compared with saline controls. Data are presented as mean ± SEM. Mann-Whitney U test to compare two groups; ****p < 0.0001
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CMH are primarily found to be associated with a rup-
ture in the cerebral vessel wall that allows extravasation
of RBC into the brain parenchyma [28]. In our model,
LPS-induced CMH were significantly associated with
endothelial activation (determined by measuring ICAM-
1 immunoreactivity) and BBB disruption (determined by
measuring brain IgG immunoreactivity). Further, larger
CMH were associated with a larger BBB disruption. LPS
can trigger an inflammatory response within the brain
parenchyma, and studies show that neuroinflammation
is associated with microvascular injury and microhemor-
rhage development [29, 30]. In the present study, endo-
thelial damage along with neuroinflammation (evident
from the increase in microglia/macrophage- and
astrocyte-positive immunoreactivity in LPS-treated
mice) were significantly associated with CMH develop-
ment, indicating a role for BBB injury and neuroinflam-
mation in the pathogenesis of LPS-induced CMH.
In the current study, LPS-induced CMH developed at
the level of both the cerebral capillaries (vessel diameter
<10 μm) [31] and larger vessels (vessel diameter
>10 μm) [32].The majority of the vessels associated with
LPS-induced CMH were <10 μm in diameter, suggesting
that brain capillaries [31] are more susceptible to LPS-
induced CMH development in this model. Our finding
of a capillary involvement in CMH development is con-
sistent with recent rodent studies in which hypertension-
and hypoxia-induced CMH were also localized around
cerebral microvessels [5, 33].
Existing mouse models of CMH include mice that
over-express mutant amyloid precursor protein to study
cerebral amyloid angiopathy (CAA)-associated CMH [2],
hypertensive mice [5] to study hypertension-associated
CMH, and the hypoxia-reoxygenation-induced CMH
mouse model to study high-altitude-associated CMH
[33]. In the CAA mouse model, mice spontaneously de-
velop PB-positive lesions by 15–24 months of age [2]
and development of CMH can be exacerbated by passive
immunization [3, 34] or by inducing bilateral common
carotid artery stenosis [4]. Two-photon-excited micros-
copy has been used to induce localized cortical CMH
[35], and hyperhomocysteinemia (HHcy) has also been
Fig. 4 Sub-acute Prussian blue-positive cerebral microhemorrhages:
Significantly higher number of PB-positive stains in LPS (1 mg/kg, at
0, 6, and 24 h; n=9)- compared with saline-treated (n=9) mice (com-
parisons shown in black) (a). Differences in regional distribution of PB-
positive stains in the cortex, sub-cortex, and cerebellum
of LPS- and saline-treated mice (comparisons shown in blue) (a).
Representative images showing PB-positive stains in different brain
regions (b). Scale bar = 100 μm. Significantly higher PB-positive area
in the LPS- compared with saline-treated mice (c). Data are presented
as mean ± SEM. Mann-Whitney U test to compare two groups and
two-way repeated measure ANOVA with Bonferroni’s post-test for
more than two groups; *p < 0.05, **p < 0.01, ****p < 0.0001
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Table 1 Correlation between ICAM-1-, IgG-, Iba1-, and GFAP-positive area with the (a) number of CMH, (b) CMH size, and (c)









No. of CMH/section 0.86*** 0.38 0.85*** 0.83**
CMH size (μm2) 0.31 0.56* 0.72** 0.62*
CMH-positive area (% total area) 0.70** 0.53* 0.88*** 0.85***
One-tailed p values: *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 5 Neuroinflammation and CMH development: Significantly higher Iba1 (left panel)- and GFAP (right panel)-positive immunoreactive area in
the LPS-treated mice (n = 7) (3 mg/kg, at 0, 6, and 24 h) compared with saline controls (n = 4) (a) in the 2-day model. Representative images showing
Iba1 (left)- and GFAP (right)-positive immunoreactive area in the saline (b)- and LPS (c)-treated mice (scale bar = 50 μm; images were
taken at ×20). The CMH number was significantly associated with both Iba1 (left)- and GFAP (right)-positive immunoreactive area in the
2-day model (3 mg/kg, at 0, 6, and 24 h) (d). Data are presented as mean ± SEM. Student’s t test to compare two groups; ****p < 0.0001;
one-tailed Spearman rho correlation for correlation analysis
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used to produce CMH [36]. One commonality between
the existing mouse models of CMH and the present
LPS-induced mouse model is inflammation. CMH devel-
opment was found to be associated with an enhanced
M1-type neuroinflammatory response in the CAA
mouse model, with increased microglial activation and
brain cytokine levels in the HHcy mouse model, and a
rapid inflammatory response up to 200 μm from CMH
in the two-photon-excited microscopy mouse model.
These observations are consistent with the current
model where we observed a significant association
between markers of neuroinflammation (microglia/
macrophage and astrocytes) and CMH development.
In the existing rodent models [2, 3, 34, 36] and clinic-
ally [6], PB staining for hemosiderin is commonly used
to detect old CMH in post mortem brain tissues. Fur-
ther, the current standardized method used to visualize
cerebral microbleeds in humans is MRI, which relies on
the paramagnetic properties of hemosiderin. Detection
of hemosiderin in brain tissue is thus crucial to develop
a clinically relevant mouse model of cerebral micro-
bleeds. PB-positive lesions cannot be detected 2 days
after LPS injection [15], and we thus modified the dosing
regimen and extended our study to 7 days to detect PB-
positive lesions and cerebral microbleeds using MRI in
our model. C57BL/6 mice treated with a triple intraperi-
toneal dose of LPS (1 mg/kg at 0, 6, and 24 h) showed
robust development of PB-positive lesions at 7 days with
no mortality. Visualization of LPS-induced CMH at
7 days using MRI demonstrates and confirms radiologic-
ally the presence of cerebral microbleeds in the current
model.
Clinically, typical CMH location is associated with
distinct underlying vascular pathologies: hypertensive
vasculopathy is associated with CMH that are located in
the basal ganglia, thalamus, cerebellum, and brain stem,
while CAA is associated with lobar CMH [1]. Varied
neuroanatomical CMH distribution is also observed in
hypoxia-reoxygenation- and hypertension-induced CMH
mouse models; however, CMH density in these models
is higher in the cortex or the olfactory bulb [5, 33]. In
Fig. 6 Ex vivo fluorescence and second-harmonic generation
imaging showing SHG of collagen (blue color), fluorescence of GFP
in endothelial cells (green), and PKH26 fluorescence marker in red
blood cells (red) in the brains of saline (a) and triple-dose (3 mg/kg
at 0, 6, and 24 h) LPS-treated Tie2-GFP mice sacrificed at 2 days (b).
All images are 3D reconstructions in enface (or true focus) geometry.
Asterisk sign indicates RBC confined within the brain vasculature in a
saline mouse (a), and arrows indicate extravasation of RBC from the
brain vasculature into the brain parenchyma in a LPS-treated mouse
(b). Superior perspective of 3D surface renderings of brain showing
distribution of cerebral microbleeds (in red) in mice from the 7-day
experiment treated with a triple-dosing regimen of LPS (1 mg/kg at
0, 6, and 24 h) (c) using T2*-weighted 3D FLASH MRI
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the current LPS model, we saw widespread distribution
of both H&E- and PB-positive lesions. The regional dis-
tribution patterns of both H&E- and PB-positive lesions
were similar with maximum CMH density in the cere-
bellum and the brain stem region followed by the cere-
brum (sub-cortex and cortex). Surface CMH that were
grossly visible on the brain surface post-LPS treatment
were also significantly higher in the cerebellum and
brain stem region. The presence of surface CMH sug-
gests a phenomenon similar to cortical superficial side-
rosis [37], and more extensive analysis of these lesions
by MRI will clarify whether the processes are fundamen-
tally similar. Though the mechanisms underlying the
observed regional distribution pattern of CMH in the
current study are not clear, higher distribution in the
cerebellum most likely relates to the vulnerability of
cerebellum blood vessels to inflammation.
Conclusions
Compared to the existing mouse models of CMH, the
current model appears to offer considerable advantages.
The LPS-induced mouse model is inflammation-based
(not limited to CAA-, hypoxic brain injury-, or
hypertension-induced CMH), non-invasive, and shows
rapid (2 and 7 days) development of CMH with negli-
gible mortality. Our work shows that LPS-induced CMH
are primarily associated with cerebral capillaries, and
BBB dysfunction and neuroinflammation play a role in
CMH development in this model. Additionally, the
cerebellum/brain stem region is more susceptible to
LPS-induced CMH development. The ease of develop-
ment of both H&E- and PB-positive CMH, and MRI-
visible cerebral microbleeds makes the LPS-induced
mouse model suitable to study the pathophysiology of
inflammation-induced CMH.
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